Andrew Hall
Chief Executive Officer chez IMV INC.
Fortune : 12 $ au 31/12/2023
Postes actifs de Andrew Hall
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMV INC. | Director/Board Member | 01/01/2022 | - |
| Chief Executive Officer | 04/08/2021 | - | |
| Corporate Officer/Principal | 10/11/2020 | 04/08/2021 |
Historique de carrière de Andrew Hall
Anciens postes connus de Andrew Hall
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | - | - |
| CELGENE | Corporate Officer/Principal | - | - |
Formation de Andrew Hall
| University of Melbourne | Undergraduate Degree |
| RMIT University | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Australie | 3 |
| Canada | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IMV INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
- Bourse
- Insiders
- Andrew Hall
- Expérience
